Company intelligence / Profile preview

TAG1

St. Louis, Missouri, USAtag1consulting.com ↗

Ownership: Private
Development stage: Other

Overview

TAG1 has developed a proprietary generator to decentralize and scale the production of high-purity Lead‑212 isotope, addressing critical supply bottlenecks in targeted alpha radiotherapy. Their technology enables reliable access to this key radioisotope for biotech innovators, hospitals, and research institutions developing next-generation cancer treatments. The company is not itself running therapeutic trials but is an essential enabler for those that do. No direct clinical results as they are not a therapeutics developer.

Therapeutic areas: OncologyRare Diseases
Modalities: RadiopharmaceuticalRadioisotope therapy (Lead-212, Bismuth-213)
Industry: Chemicals & Materials

Partnerships

NRG PALLAS – strategic partnership to secure Radium‑224 supply for Lead‑212 production

Beyond the preview

Go deeper on TAG1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAG1.

Explore the full profile